anti-CD19 CAR NK cells
Phase 2Cell therapy
anti-CD19 CAR NK cells is one of 216 biologic programs targeting Autoimmune. It is currently in Phase 2.
8
Indications
12
Total Trials
9
Active Trials
215
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
181 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1anti-CD19 CAR NK cells
PPersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Voltaren
NovartisPreclinical
Cataflam
NovartisPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma2 trials
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Unknown status·—·Phase 1·NCT05673447·12 enrolled
Systemic Lupus Erythematosus2 trials
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
Recruiting·—·Phase 1·NCT06010472·36 enrolled
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06421701·10 enrolled
Central Nervous System Lymphoma1 trial
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
Enrolling by invitation·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06827782·42 enrolled
Immune Thrombocytopenia1 trial
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
Recruiting·—·Phase 1·NCT06337474·9 enrolled
Autoimmune Disease1 trial
An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Recruiting·—·Phase 1·NCT06464679·72 enrolled
5 more indications
Rheumatoid Arthritis1 trial
Leukemia1 trial
Cell Therapy1 trial
Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL
Not yet recruiting·SShahid Beheshti University of Medical Sciences·Phase 1/2·NCT06631040·10 enrolled
Autoimmune1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-CD19 CAR NK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details